RETROSPECTIVE ANALYSIS OF THE CHEMOTHERAPY FOR PATIENTS OF EXTENSIVE SMALL CELL LUNG CANCER WITH POOR PERFORMANCE STATES

    loading  Checking for direct PDF access through Ovid

Abstract

Backgrounds

Small-cell lung carcinoma is recognized as a malignant tumor with high sensitivity to anticancer drug, and it is recommended strongly to carry out the systemic chemotherapy for patients of small-cell lung cancer with enough general condition. However, there are few evidence of the efficiency and toxicity of the chemotherapy for cases presenting poor PS.

Methods

We reviewed medical charts of patients of extensive small-cell lung cancer with poor PS (ECOG;3,4) treated by systemic chemotherapy from April 2002 to January 2012 at Metropolitan Komagome Hospital.

Result

The characteristics of the 16 cases were median age 74.5 years, 12 cases with PS 3, 4 cases with PS 4. All cases carried out at least one cycle of chemotherapy including platinum drug.

Results and conclusions

Previously, the medium survival time for patients of extensive small-cell lung cancer with only best supportive care is reported to be 1–2 months. Our investigation suggested that systemic chemotherapy contributes to the extension of survival time even among cases with poor PS; therefore, chemotherapy can be considered for patients who wish life prolongation.

Related Topics

    loading  Loading Related Articles